Atlas Trials

Santen Pharmaceutical (Taiwan) Co., LTD

2 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Santen Pharmaceutical (Taiwan) Co., LTD

RecordFirmDate
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting (NCT04828057)Santen Pharmaceutical (Taiwan) Co., LTD2021-09-01
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution) (NCT04737928)Santen Pharmaceutical (Taiwan) Co., LTD2018-04-02

Track Santen Pharmaceutical (Taiwan) Co., LTD automatically

Every clearance here is in the API, with alerts when new ones post.